Clinical Trial

Evaluation of the Safety of LipiodolⓇ Embolization in Symptomatic Digital Osteoarthritis Refractory to Conventional Treatment

Study acronym: EMBARDI
Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The goal of this clinical trial is to evaluate the safety of arterial embolization using Lipiodol® in patients with symptomatic hand osteoarthritis refractory to conventional treatment. It will also learn about the efficacy of arterial embolization with Lipiodol® in reducing pain and improving hand function. The main questions it aims to answer are: * What are the side effects and complications associated with the Lipiodol® arterial embolization procedure? * Does arterial embolization reduce pain intensity and improve hand function? Researchers will evaluate patients over a 6-month period to assess the safety of Lipiodol® embolization and its impact on joint pain, swelling, and functional capacity. Participants will: * Undergo arterial embolization with Lipiodol® * Participate in regular follow-ups to monitor pain relief, hand function, and any side effects * Have imaging studies to assess changes in joint vascularisation and damage
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2024-09-20; most recent amendment 2026-05-04.
Status change: Not Yet Recruiting → Recruiting 2024-12-05
Trial Details
NCT Number NCT06611007
Lead Sponsor University Hospital, Grenoble
Conditions Osteoarthritis
Enrollment 15 participants
Start Date 2025-01-30
Primary Completion 2028-07-15 (estimated)
Study Completion 2028-07-15 (estimated)
Updated on ClinicalTrials.gov 2026-05-05